2022 Danaher Summit: Genomes to Cures

Dr. Siddhartha Mukherjee M.D. DPhil, Department of Medicine, Columbia University

An overview of the past, present and future of genomic medicines and discuss the societal and ethical obligations for global democratization of these potentially curative therapies.

George Church, Ph.D.

“Convergence” involves combining technological and social innovation in ways that guide divergent, out-of-the-box ideas into daily life. Ideally, this convergence will create solutions that improve health care, while reducing costs and social inequities. The future of medicine promises to bring more convergent innovations that will revolutionize health care.

Andrew W. Lo

We’re experiencing a Golden Age of Biomedicine, but the funding and business models we use to commercialize these technologies have barely changed, making it challenging for younger scientists and entrepreneurs to bring their most innovative ideas into practice. Professor Lo describes the financial considerations that create bottlenecks in commercialization, delivery and reimbursement, as well as current and emerging solutions, including venture philanthropy, portfolio companies, securitization techniques and new payment models.

Moderated by Conor McKechnie

Panelists:
Mitchell Finer, ElevateBio  
Doug Ingram, Sarepta 
Eliana Clark, Intellia 
Katy Rezvani, MD Anderson Cancer Center 
Sonia Vallabh, Mass General Hospital, Broad Institute

This panel covers the current challenges that drug developers  face in advancing potential life-saving treatments to patients, with specific focus on biomanufacturing and regulatory guidance. Panelists  also discuss opportunities to change the paradigm of drug development and to implement sustainable manufacturing of genomic medicines.

Moderated by JC Gutierrez-Ramos

Panelists: 
Carl June, University of Pennsylvania 
George Church, Harvard Medical School 
Fyodor Urnov, Innovative Genomic Institute, Berkeley University 
Peter Marks, CBER at the FDA

Panelists provide their perspectives on the programs and the platforms that have the biggest potential to provide therapeutic benefits, with line of sight for smooth regulatory pathways. We discuss a future of highly personalized therapeutics, its implications, and the role and responsibilities for all involved parties—and, importantly, opportunities for new regulatory frameworks to enable this new wave of therapeutic advances.